Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...